Responding to rising drug prices and persistent shortages, a dozen large hospital systems have joined Civica Rx, a fledgling not-for-profit generic manufacturer that was created last year by seven other big hospital groups with $100 million in backing from philanthropic organizations. All totaled, about 750 U.S. hospitals have joined the effort.

The move is the latest sign of growing frustration among hospitals over pricing practices and quality-control issues that have hampered budgets and patient care. “Drug shortages have become a national crisis where patient treatments and surgeries are canceled, delayed or suboptimal,” said Martin VanTrieste, a former Amgen (AMGN) executive, who was hired to run the effort, in a statement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy